We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
+41.7%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
–
AUM
$455M
AUM Growth
+$74.1M
Cap. Flow
-$12.9M
Cap. Flow %
-2.84%
Top 10 Hldgs %
70.66%
Holding
34
New
11
Increased
3
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$11.7M
2
ICLR icon
Icon
ICLR
+$11.5M
3
KYMR icon
Kymera Therapeutics
KYMR
+$9.2M
4
ATAI
AtaiBeckley Inc
ATAI
+$7.92M
5
QURE icon
uniQure
QURE
+$7.92M

Top Sells

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$21M
2
ARGX icon
argenx
ARGX
+$12.6M
3
INSM icon
Insmed
INSM
+$11.1M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.8M
5
AKRO
Akero Therapeutics
AKRO
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$60B
$52.8M 11.59%
62,730
-14,700
-19% -$12.6M
ICLR icon
2
Icon
ICLR
$13.3B
$45M 9.89%
247,090
+64,500
+35% +$11.5M
NTRA icon
3
Natera
NTRA
$59.5B
$42M 9.23%
183,264
-20,400
-10% -$4.26M
INSM icon
4
Insmed
INSM
$25.7B
$36.7M 8.07%
210,900
-60,700
-22% -$11.1M
ILMN icon
5
Illumina
ILMN
$40.8B
$30.3M 6.66%
231,161
-91,100
-28% -$10.7M
GH icon
6
Guardant Health
GH
$23.8B
$29M 6.38%
284,100
– –
NBIX icon
7
Neurocrine Biosciences
NBIX
$14.1B
$23.1M 5.07%
162,800
– –
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.7B
$21.8M 4.79%
366,812
– –
FTRE icon
9
Fortrea Holdings
FTRE
$1.89B
$21M 4.62%
1,218,560
+229,788
+23% +$2.84M
BBIO icon
10
BridgeBio Pharma
BBIO
$12.8B
$19.8M 4.36%
259,300
– –
SRRK icon
11
Scholar Rock
SRRK
$5.92B
$16M 3.52%
363,300
– –
EXAS
12
DELISTED
Exact Sciences
EXAS
$15M 3.3%
147,750
-123,200
-45% -$9.89M
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
$11.1M 2.44%
+275,090
New +$6.36M
KYMR icon
14
Kymera Therapeutics
KYMR
$9.31B
$10.6M 2.33%
+136,300
New +$9.2M
CMPS
15
Compass Pathways
CMPS
$1.81B
$10.5M 2.3%
1,519,388
+583,938
+62% +$3.56M
PRCT icon
16
Procept Biorobotics
PRCT
$985M
$9.7M 2.13%
308,434
– –
RVMD icon
17
Revolution Medicines
RVMD
$43.9B
$9.23M 2.03%
+115,900
New +$7.6M
LEGN icon
18
Legend Biotech
LEGN
$3.72B
$8.88M 1.95%
+408,652
New +$11.7M
ATAI
19
DELISTED
AtaiBeckley Inc
ATAI
$6.86M 1.51%
+1,678,400
New +$7.92M
SLNO
20
DELISTED
Soleno Therapeutics
SLNO
$6.26M 1.37%
+135,100
New +$7.41M
PTGX icon
21
Protagonist Therapeutics
PTGX
$9.18B
$5M 1.1%
+57,300
New +$4.69M
QURE icon
22
uniQure
QURE
$2.65B
$4.91M 1.08%
+205,247
New +$7.92M
PRAX icon
23
Praxis Precision Medicines
PRAX
$7.84B
$4.41M 0.97%
+14,951
New +$2.78M
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$2.58M 0.57%
103,100
– –
ISRG icon
25
Intuitive Surgical
ISRG
$143B
$2.49M 0.55%
4,390
– –
1
2

Similar funds

VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
PCTC
Perkins Coie Trust Company Seattle, Washington $603M AUM 23.96% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return
OPWM
Oakwell Private Wealth Management Austin, Texas $603M AUM 24.07% 1-Year Est. Return
F1I
Fund 1 Investments Rincon, Puerto Rico $603M AUM 62.42% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Eagle Health Investments's Q4 2025 Portfolio in Review

As of Q4 2025, Eagle Health Investments held 34 positions worth $455M, up 19% from $381M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Eagle Health Investments's Q4 2025 filing shows 11 new, 3 increased, 5 reduced and 4 closed positions. Its largest new stake was Legend Biotech: 408,652 shares worth $8.88M. The largest sale was Ultragenyx Pharmaceutical, an estimated $21M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Eagle Health Investments's largest Q4 2025 buy was Legend Biotech: 408,652 shares worth $8.88M.
  • Eagle Health Investments added most to Icon in Q4 2025, an estimated $11.5M increase.
  • Eagle Health Investments's biggest Q4 2025 reduction was argenx, cutting an estimated $12.6M.
  • Eagle Health Investments fully exited Ultragenyx Pharmaceutical in Q4 2025, selling an estimated $21M.
  • Eagle Health Investments's ten largest holdings make up 71% of its $455M portfolio in Q4 2025.
  • Eagle Health Investments opened 11 new positions and closed 4 in Q4 2025.
  • Eagle Health Investments's portfolio value rose 19% quarter-over-quarter to $455M.

Based on Eagle Health Investments's 13F filing for Q4 2025, filed 6 Feb 2026.